HER-2 gene amplification can be acquired as breast cancer progresses

Songdong Meng, Debasish Tripathy, Sanjay Shete, Raheela Ashfaq, Barbara Haley, Steve Perkins, Peter Beitsch, Amanullah Khan, David Euhus, Cynthia Osborne, Eugene Frenkel, Susan Hoover, Marilyn Leitch, Edward Clifford, Ellen Vitetta, Larry Morrison, Dorothee Herlyn, Leon W M M Terstappen, Timothy Fleming, Tanja Fehm & 4 others Thomas Tucker, Nancy Lane, Jianqiang Wang, Jonathan Uhr

Research output: Contribution to journalArticle

403 Citations (Scopus)

Abstract

Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 ± 2.72 vs. 2.8 ± 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.

Original languageEnglish (US)
Pages (from-to)9393-9398
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number25
DOIs
StatePublished - Jun 22 2004

Fingerprint

erbB-2 Genes
Circulating Neoplastic Cells
Gene Amplification
Breast Neoplasms
Neoplasms
Chromosomes, Human, Pair 2
Hematologic Tests
Fluorescence In Situ Hybridization
Oncogenes
Biomarkers
Confidence Intervals
Neoplasm Metastasis
Antibodies

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

HER-2 gene amplification can be acquired as breast cancer progresses. / Meng, Songdong; Tripathy, Debasish; Shete, Sanjay; Ashfaq, Raheela; Haley, Barbara; Perkins, Steve; Beitsch, Peter; Khan, Amanullah; Euhus, David; Osborne, Cynthia; Frenkel, Eugene; Hoover, Susan; Leitch, Marilyn; Clifford, Edward; Vitetta, Ellen; Morrison, Larry; Herlyn, Dorothee; Terstappen, Leon W M M; Fleming, Timothy; Fehm, Tanja; Tucker, Thomas; Lane, Nancy; Wang, Jianqiang; Uhr, Jonathan.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 25, 22.06.2004, p. 9393-9398.

Research output: Contribution to journalArticle

Meng, S, Tripathy, D, Shete, S, Ashfaq, R, Haley, B, Perkins, S, Beitsch, P, Khan, A, Euhus, D, Osborne, C, Frenkel, E, Hoover, S, Leitch, M, Clifford, E, Vitetta, E, Morrison, L, Herlyn, D, Terstappen, LWMM, Fleming, T, Fehm, T, Tucker, T, Lane, N, Wang, J & Uhr, J 2004, 'HER-2 gene amplification can be acquired as breast cancer progresses', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 25, pp. 9393-9398. https://doi.org/10.1073/pnas.0402993101
Meng, Songdong ; Tripathy, Debasish ; Shete, Sanjay ; Ashfaq, Raheela ; Haley, Barbara ; Perkins, Steve ; Beitsch, Peter ; Khan, Amanullah ; Euhus, David ; Osborne, Cynthia ; Frenkel, Eugene ; Hoover, Susan ; Leitch, Marilyn ; Clifford, Edward ; Vitetta, Ellen ; Morrison, Larry ; Herlyn, Dorothee ; Terstappen, Leon W M M ; Fleming, Timothy ; Fehm, Tanja ; Tucker, Thomas ; Lane, Nancy ; Wang, Jianqiang ; Uhr, Jonathan. / HER-2 gene amplification can be acquired as breast cancer progresses. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 25. pp. 9393-9398.
@article{0af0801597e64eb0a84b8d2033aebdff,
title = "HER-2 gene amplification can be acquired as breast cancer progresses",
abstract = "Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97{\%} agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 ± 2.72 vs. 2.8 ± 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5{\%} (95{\%} confidence interval of 18.8-59.4{\%}). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.",
author = "Songdong Meng and Debasish Tripathy and Sanjay Shete and Raheela Ashfaq and Barbara Haley and Steve Perkins and Peter Beitsch and Amanullah Khan and David Euhus and Cynthia Osborne and Eugene Frenkel and Susan Hoover and Marilyn Leitch and Edward Clifford and Ellen Vitetta and Larry Morrison and Dorothee Herlyn and Terstappen, {Leon W M M} and Timothy Fleming and Tanja Fehm and Thomas Tucker and Nancy Lane and Jianqiang Wang and Jonathan Uhr",
year = "2004",
month = "6",
day = "22",
doi = "10.1073/pnas.0402993101",
language = "English (US)",
volume = "101",
pages = "9393--9398",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "25",

}

TY - JOUR

T1 - HER-2 gene amplification can be acquired as breast cancer progresses

AU - Meng, Songdong

AU - Tripathy, Debasish

AU - Shete, Sanjay

AU - Ashfaq, Raheela

AU - Haley, Barbara

AU - Perkins, Steve

AU - Beitsch, Peter

AU - Khan, Amanullah

AU - Euhus, David

AU - Osborne, Cynthia

AU - Frenkel, Eugene

AU - Hoover, Susan

AU - Leitch, Marilyn

AU - Clifford, Edward

AU - Vitetta, Ellen

AU - Morrison, Larry

AU - Herlyn, Dorothee

AU - Terstappen, Leon W M M

AU - Fleming, Timothy

AU - Fehm, Tanja

AU - Tucker, Thomas

AU - Lane, Nancy

AU - Wang, Jianqiang

AU - Uhr, Jonathan

PY - 2004/6/22

Y1 - 2004/6/22

N2 - Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 ± 2.72 vs. 2.8 ± 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.

AB - Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2-positive tumors, the HER-2/chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 ± 2.72 vs. 2.8 ± 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2-negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.

UR - http://www.scopus.com/inward/record.url?scp=3042552362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042552362&partnerID=8YFLogxK

U2 - 10.1073/pnas.0402993101

DO - 10.1073/pnas.0402993101

M3 - Article

VL - 101

SP - 9393

EP - 9398

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 25

ER -